Novel polypeptides for promoting tissue repair and uses thereof
Novel polypeptides with disulfide bonds address the stability and cost issues of current treatments by promoting tissue repair and improving skin health, offering effective and stable solutions for wounds and ulcers.
Patent Information
- Application Number
- JP2024531116
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-25
- Filing Date
- 2022-04-08
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-04-08
AI Technical Summary
Current treatments for intractable wounds and ulcers, such as burns, gastric ulcers, and oral ulcers, are expensive and have poor stability, limiting their clinical application.
Development of novel polypeptides (TRF1-TRF12) with specific structures containing disulfide bonds, which are chemically stable and promote tissue repair by enhancing cell proliferation and migration.
The novel polypeptides effectively promote tissue repair, treat wounds and ulcers, and improve skin appearance with low toxicity and no significant side effects, while being easily synthesizable in large quantities.
Smart Images

Figure 2024543723000012 
Figure 2024543723000013 
Figure 2024543723000014
Abstract
Description
[Technical field]
[0001] The present invention relates to the fields of pharmaceuticals, medical devices and everyday chemicals, and in particular to novel polypeptides for promoting tissue repair and uses thereof. [Background technology]
[0002] With the accelerated development of society and the aging of society, tissue trauma includes not only trauma such as burns and wounds, but also intractable wounds and ulcers such as gastric ulcers, oral ulcers, diabetic ulcers, autoimmune skin ulcers, venous stasis ulcers, and bed sores caused by long-term bed rest. The pathology of intractable wounds and ulcers is complex, the course is long, the treatment is difficult, and the treatment costs are high, which brings physical and mental pressure and economic burden to patients. At present, growth factor preparations are widely used in the treatment of intractable wounds and ulcers and have good therapeutic effects, among which epidermal growth factor, basic fibroblast growth factor, and vascular endothelial growth factor are all important for the healing of wounds and ulcers, but these endogenous factors have high preparation costs and poor stability, which limits their clinical application. Therefore, there is a great need to find and develop active substances with high activity, low production costs, and excellent stability for the treatment of tissue trauma and intractable wounds and ulcers. Summary of the Invention [Problem to be solved by the invention]
[0003] An object of the present invention is to overcome the above-mentioned drawbacks of the prior art and to provide a novel polypeptide capable of promoting tissue repair and uses thereof. [Means for solving the problem]
[0004] In order to achieve the above object, the present invention employs the following technical means.
[0005] The novel polypeptides for promoting tissue repair, designated TRF1-TRF12, have the structure shown in Formula I: JPEG2024543723000001.jpg1963In formula I, R1=H or Ala or Gly or Ala-Ala- or Val-Ala-; R2 = Asn or Asp; R3=Ser or Tyr or -Gly-Ser-Tyr or -Gly-Ser-Tyr-Ala-Pro-Leu-Gly-Tyr or -Gly-Ser-Tyr-Ala-Pro-Leu-Gly-Tyr- His-Val-Arg or -Gly-Ser-Tyr-Ala-Pro-Leu-Gly-Tyr-His-Val-Arg-Glu-Tyr-Pro-Ala-Gly-Val-Ser-Ala-Ala.
[0006] Furthermore, in a preferred embodiment of the present invention, the novel polypeptide compounds include, but are not limited to, TRF1 to TRF12 shown below. JPEG2024543723000002.jpg91154
[0007] The novel polypeptides (TRF1 to TRF12) can be prepared by methods well known in the art, and can be chemically synthesized using a polypeptide synthesizer, or can be biosynthesized by deducing the nucleotide sequence from the polypeptide sequence and cloning it into an expression vector.
[0008] Another object of the present invention is to disclose the use of said novel polypeptides (TRF1 to TRF12) in the preparation of products for promoting tissue repair or improving skin aesthetics.
[0009] Preferably, the novel polypeptides (TRF1 to TRF12) are used in the preparation of products for treating wounds, burns, ulcers or for improving the appearance of the skin.
[0010] Preferably, the product is a pharmaceutical product, a medical device or a daily chemical product.
[0011] Preferably, the pharmaceutical, medical device, or daily chemical product contains an effective amount of one or more novel polypeptides (TRF1 to TRF12), or a pharma- ceutically acceptable salt or stereoisomer thereof, with the remainder being an additive or other compoundable drug.
[0012] Said additives are conventional additives such as solvents, disintegrants, taste correctors, preservatives, colorants, binders, etc.
[0013] The drugs that can be included include other natural medicines, chemical drugs, and biological drugs.
[0014] The pharmaceuticals, medical devices, or daily chemicals may be in the form of tablets, capsules, injections, liposome nanoparticles, controlled release agents, gel creams, ointments, liniments, patches, creams, cleansers, lotions, gels, skin lotions, etc. Effect of the Invention
[0015] The present invention has the following advantages and effects over the prior art. (1) The polypeptides of the present invention (TRF1 to TRF12) are polypeptides having a new structure. All of these novel polypeptides contain disulfide bonds, are structurally stable, and are not easily degraded. (2) The novel polypeptides (TRF1 to TRF12) according to the present invention significantly promote the proliferation of immortalized human epidermal cells (HaCAT) and also significantly promote the migration of human dermal fibroblasts (HSF), and thus have a tissue repair promoting effect. (3) The novel polypeptides (TRF1 to TRF12) according to the present invention can be used to promote tissue repair and treat peptic ulcers and oral ulcers, and have the effect of removing wrinkles, scars, and pigmentation. (4) The novel polypeptides (TRF1 to TRF12) according to the present invention have low toxicity, and no obvious toxic side effects were observed when orally administered at 500 mg / kg. (5) The novel polypeptides (TRF1 to TRF12) according to the present invention can be chemically or biosynthetically synthesized, and can be easily prepared in large quantities. [Brief description of the drawings]
[0016] [Figure 1] FIG. 1 shows mass spectra of the novel polypeptide TRF1, where A shows its ESI-MS, B shows its MS2 (m / z 50-580), and C shows its MS2 (m / z 580-1110). [Diagram 2] FIG. 1 shows mass spectra of the novel polypeptide TRF2, where A shows its ESI-MS, B shows its MS2 (m / z 50-420), C shows its MS2 (m / z 390-810), and D shows its MS2 (m / z 810-1170). [Diagram 3] FIG. 1 shows mass spectra of the novel polypeptide TRF3, where A shows its ESI-MS, B shows its MS2 (m / z 50-600), and C shows its MS2 (m / z 600-1300). [Figure 4] FIG. 1 shows mass spectra of the novel polypeptide TRF4, where A shows its ESI-MS, B shows its MS2 (m / z 50-510), and C shows its MS2 (m / z 510-1250). [Diagram 5] FIG. 1 shows mass spectra of the novel polypeptide TRF5, where A shows its ESI-MS, B shows its MS2 (m / z 50-650), and C shows its MS2 (m / z 620-1200). [Figure 6] FIG. 1 shows mass spectra of the novel polypeptide TRF6, where A shows its ESI-MS, B shows its MS2 (m / z 50-400), C shows its MS2 (m / z 400-900), and D shows its MS2 (m / z 850-1800). [Figure 7] FIG. 1 shows mass spectra of the novel polypeptide TRF7, where A shows its ESI-MS, B shows its MS2 (m / z 50-400), C shows its MS2 (m / z 400-970), and D shows its MS2 (m / z 970-1700). [Figure 8] FIG. 1 shows mass spectra of the novel polypeptide TRF8, where A shows its ESI-MS, B shows its MS2 (m / z 50-620), and C shows its MS2 (m / z 620-1150). [Figure 9] FIG. 1 shows mass spectra of the novel polypeptide TRF9, where A shows its ESI-MS, B shows its MS2 (m / z 50-420), C shows its MS2 (m / z 390-810), and D shows its MS2 (m / z 800-1200). [Figure 10] FIG. 1 shows mass spectra of the novel polypeptide TRF10, where A shows its ESI-MS, B shows its MS2 (m / z 50-500), and C shows its MS2 (m / z 450-1250). [Figure 11] FIG. 1 shows mass spectra of the novel polypeptide TRF11, where A shows its ESI-MS, B shows its MS2 (m / z 50-420), C shows its MS2 (m / z 390-820), and D shows its MS2 (m / z 800-1270). [Figure 12] FIG. 1 shows mass spectra of the novel polypeptide TRF12, with A showing its ESI-MS, B showing its MS2 (m / z 50-380), C showing its MS2 (m / z 380-920), and D showing its MS2 (m / z 920-1560). [Figure 13] FIG. 1 shows the results of analyzing the effects of novel polypeptides TRF1 to TRF12 on the proliferation of HaCAT cells. [Figure 14] FIG. 1 shows the results of analyzing the effects of novel polypeptides TRF1 to TRF12 on the migration of HSF cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described in detail below with reference to the drawings based on embodiments, but the present invention is not limited to these embodiments.
[0018] Example 1 Synthesis of novel polypeptides TRF1 to TRF12 (1) Solid-phase synthesis of novel polypeptide TRF1 0.3-0.5 mmol / g of tyrosine-Wang resin with Fmoc group and side chain protecting group was placed in a solid phase synthesis machine, and 20 mL of N,N-dimethylformamide was added to completely dissolve it. After extracting the solvent, 20% piperidine (dissolved in N,N-dimethylformamide by volume ratio) was added, and the mixture was stirred for about 10 minutes, after which the solvent was extracted, and this operation was repeated twice to completely remove the Fmoc group, after which 20 mL of N,N-dimethylformamide was added to wash, the solvent was extracted, and this operation was repeated three times. 0.5 mmol of cysteine with Fmoc group and side chain protecting group was added, and the same amount of HBTU / N,N-dimethylformamide and N,N-diisopropylethylamine / N,N-dimethylformamide solutions were further added, and the mixture was reacted for 40-60 minutes under N2 atmosphere. Unreacted drugs and reagents were eluted with N,N-dimethylformamide and detected with ninhydrin. The remaining amino acids were then bonded in the same manner, and the peptide bonded to the resin was synthesized through steps such as deprotection, activation, condensation, and washing. Cleavage solution (trifluoroacetic acid / triisopropylsilane / pure water / 1,2-ethanedithiol, volume ratio 94:2.5:2.5:1) was added to the peptide on the resin and cleavage treatment was performed for 2 to 3 hours, after which ice-cold ethyl ether was added and centrifugation was performed to obtain a precipitate in the lower layer. The precipitate was taken out and the remaining trifluoroacetic acid was removed, after which a specified amount of iodine solution was added and the reaction was stirred at room temperature for about 1 hour to obtain the crude product of the desired polypeptide. The crude polypeptide was dissolved in 20% aqueous acetonitrile, filtered, and purified by high performance liquid chromatography at detection wavelengths of 214 nm, 254 nm, and 280 nm, with a mobile phase of acetonitrile-water (v / v: 10:90 to 50:50), and a flow rate of 1 mL / min. The peak of interest was collected, concentrated, and lyophilized to obtain a purified polypeptide. (2) Solid-phase synthesis of novel polypeptides TRF2 to TRF12 The synthesis process of polypeptides TRF2 to TRF12 was the same as that of TRF1 described above. An amino acid (the first one at the carboxyl terminus) having an Fmoc group and a side chain protecting group was placed in a solid-phase synthesizer at 0.3 to 0.5 mmol / g on Wang resin, and the amino acids in the sequence were sequentially linked and synthesized through the steps of deprotection, activation, condensation, and washing to obtain a polypeptide bound to the resin. The polypeptide was then cleaved and purified to obtain a purified polypeptide.
[0019] Example 2 Identification of novel polypeptides TRF1 to TRF12 by mass spectrometry The TRF1 to TRF12 polypeptides were weighed and dissolved in deionized water to prepare sample solutions with a concentration of 0.1 mg / mL. The sample solutions were each injected into an AB Sciex TripleTOF (registered trademark) 5600+ mass spectrometer for analysis. Mass range (m / z): 50 to 2000 Da, acquisition mode: positive ion mode, scan mode: selected ion scan, capillary voltage: 3.0 kV, ion source temperature: 110 °C, collision energy range: 50 to 80 V. As shown in Figures 1 to 12, a secondary scan was performed on the precursor ions, and based on the fragmentation of the secondary mass spectrum, b ions and y ions were analyzed to identify the amino acid residue sequence of the novel polypeptide.
[0020] Example 3: Promotion of HaCAT cell proliferation by novel polypeptides TRF1 to TRF12 (1) Cell inoculation: Cells in the logarithmic growth phase were selected, digested, and counted. The required number of cells was taken and an appropriate amount of medium was added to obtain a cell culture of 1 × 10 4 The cells were homogenized with a pipette gun, added to a 96-well plate (100 μL / well), and cultured in a CO2 incubator. (2) Addition of drugs: After the cells attached to the wall, the old medium was removed, and blank medium was added to the control group, EGF to the positive control group, and different concentrations of TRF1 to TRF12 were added to the drug groups. PBS was then added around the periphery of the plate, and the cells were cultured in an incubator for 48 hours using 6 wells per group. (3) Addition of MTT: The old medium was removed by suction, and 30 μL of prepared MTT (protected from light) was added per well. The wells were then placed in an incubator and incubated for 4 hours to form formazan crystals. (4) Measurement of OD value: MTT was removed, 100 μL of DMSO solution was added to each well, and the formazan was thoroughly dissolved. The absorbance was then detected using a multi-function microplate reader (detection wavelength: 595 nm). The cell viability was calculated, and the test was repeated at least three times. From the test results shown in FIG. 13, the novel polypeptides TRF1 to TRF12 exhibited a significant proliferation-promoting effect on HaCAT cells (cell proliferation rate of 114±5% to 135±3%) at low concentrations (0.08 to 2.00 μg / mL).
[0021] Example 4 Promotion of HSF cell migration by novel polypeptides TRF1 to TRF12 (1) Cell inoculation and drug addition: Transwells were UV sterilized in a clean bench for 30 minutes and then set in a 24-well plate. After digestion, the cells were counted and diluted to 2 × 10 5 The cells were diluted to a density of 100 μL / mL. Test drugs TRF1 to TRF12 and a positive control drug were added and diluted into drug-containing cell solutions of different concentrations. 100 μL of drug-containing cell solution was added to the upper chamber of the drug administration group, and 100 μL of cell solution was added to the blank group, after which 600 μL of blank medium was added to each chamber and cultured in an incubator. (2) Fixation, staining, and photography: After culturing, the medium was discarded, washed with PBS, and the cells in the lower chamber were fixed with 4% paraformaldehyde (about 30 minutes). After fixation, the cells were washed twice with PBS, and 600 μL of staining solution was added to the lower chamber of each well and stained for 20 minutes. After collecting the crystal violet and washing with PBS, the cells that did not migrate well were carefully pressed against the membrane of the upper chamber with a cotton swab and wiped off. After air drying, five areas were randomly photographed for each chamber with an inverted fluorescent microscope, and finally the average number of migrated cells was statistically analyzed using GraphPad Prism 6.0. The test results showed that the novel polypeptides TRF1 to TRF12 (2 μg / mL) could significantly promote the migration of HSF cells. After 48 hours of action, the average number of migrated cells in the drug group was in the range of 578±9 to 396±14, which was significantly higher than the control group's 132±10, showing statistical significance (P<0.05). The results are shown in Figure 14.
[0022] Example 5 Repair effect of novel polypeptide TRF7 on mouse skin wounds Fifteen male Kunming mice aged 8 to 10 weeks (purchased from the Guangdong Medical Experimental Animal Center) were selected and housed in separate cages. They were randomly divided into a control group, a positive drug administration group (Kang Fu Xin Liquid), a low-dose TRF7 administration group (0.5 mg / mL), and a high-dose TRF7 administration group (2.0 mg / mL). The mice were anesthetized, and the backs were depilated and disinfected. After that, a hole was made in the exposed skin on the backs of the mice with a 6 mm diameter punch, a circular skin including the epidermis and dermis was excised, and a transparent oxygen-permeable dressing was applied to the wound site to provide a shielding and protective effect. In the control group, saline was administered, the transparent oxygen-permeable dressing was gently lifted, 0.1 mL of liquid was added to the wound, and a new dressing was applied. The drug was administered twice a day for 10 consecutive days, the change in the size of the wound was measured every day, and the mice were sacrificed 10 days after administration. The wound healing rate is calculated as follows: Wound healing rate% = (S1 - S n ) / S1 (S1 is the wound area on the first day, S n The area of the wound on day n was calculated using the formula: JPEG2024543723000003.jpg60164Note: Compared to the model group, *P<0.05 indicates significant difference. The test results showed that the novel polypeptide TRF7 could significantly promote the healing of mouse skin wounds, with a significant difference from the control group and superior to the new recovery liquid.
[0023] Example 6 Repair effect of novel polypeptide TRF7 on mouse skin burns 15 male Kunming mice aged 8 to 10 weeks (purchased from Guangdong Provincial Health Laboratory Animal Center) were selected and kept in separate cages, fed ad libitum, and stopped eating the day before the test. The mice were coated with 13% Na2S solution and depilated, and 20 g of weight was placed in a water bath, heated to boiling, and maintained for 10 minutes. The upper end of the weight was pinched with pliers and quickly placed on the mouse's skin for 5 seconds, and slightly pressed to form a superficial second-degree burn model with an area of 2 cm x 2 cm. The next day, 0.1 mL of TRF7 (0.5 mg / mL or 2.0 mg / mL), saline, and recovery liquid with different solubilities were dripped onto the burn, and the drug was replaced once a day. Burn healing was observed on the 3rd, 5th, and 10th days. The burn healing rate was calculated according to the method of Example 5. The results are shown in Table 2. JPEG2024543723000004.jpg61165Note: Compared to the model group, *P<0.05 indicates significant difference. The test results showed that the novel polypeptide TRF7 could significantly promote the healing of skin burns in mice, with a significant difference from the control group and superior to the new recovery liquid.
[0024] Example 7 Protective effect of novel polypeptide TRF7 against stress-induced gastric ulcer in rats Test method: 20 male SD rats (purchased from Guangdong Medical Experimental Animal Center) weighing 180-210g were taken and randomly divided into blank group, model group, sucralfate administration group (1g / kg, positive drug administration group), low dose TRF7 administration group (12.5mg / kg) and high dose TRF7 administration group (50.0mg / kg). Drug administration groups were forced to give oral administration for 7 consecutive days. Rats in each group were fasted without water for 24 hours before modeling, and all groups except the control group were modeled using the restrained water immersion method. The rats in each group were fixed on a rat board and immersed vertically with their heads up in a constant temperature (20℃) water tank for 8 hours, with the water surface at the same height as the rat's xiphoid process. At the end of stress modeling, the rats were cervically dislocated, dissected, and the pylorus was ligated. The stomach was perfused with 2 mL of 10% formaldehyde solution, the cardia was ligated, and the stomach body was removed and fixed in formaldehyde solution for 15 minutes. The stomach was cut along the greater curvature, rinsed with saline, and unfolded to observe the damage of the gastric mucosa and calculate the gastric ulcer index. The ulcer index (UI) was calculated according to the Guth criteria, with pinpoint bleeding scored as 1 point, linear bleeding less than 1 mm in length scored as 2 points, 1-2 mm scored as 3 points, 2-4 mm scored as 4 points, more than 4 mm scored as 5 points, and width more than 1 mm scored as x2 points. The results are shown in Table 3. JPEG2024543723000005.jpg44142Note: Compared to the model group, *P<0.01 indicates a significant difference. The test results showed that the novel polypeptide TRF7 exhibited a significant protective effect against stress-induced gastric ulcer in rats, with a significant difference from the model group, and the protective effect was superior to that of the positive drug sucralfate.
[0025] Example 8 Protective effect of novel polypeptide TRF7 against oral ulcers in rats Test method: 15 healthy SD rats weighing 180-210g (purchased from Guangdong Medical Experimental Animal Center) were randomly divided into a model group, a positive drug administration group (Kang Fu Xin Liquid), a low dose TRF7 administration group (0.5mg / mL), and a high dose administration group (2.0mg / mL), and modeled by chemical cauterization. A plastic tube with a diameter of 5mm was taken, a small cotton ball soaked in 95% phenol solution was placed on one end of the tube, and the end of the cotton ball was fixed on the left buccal mucosa of the anesthetized rat, held for 60 seconds, and then the cauterized surface was washed with saline. After 24 hours, the formation of a round ulcer was observed on the left side of the test site, with a yellowish-white pustule formed on its surface, with a clear border around it, the surrounding mucosa was red, swollen, and congested, the ulcer surface diameter was >3mm, and the model was successfully established. The ulcer surface of the test group, model group, and positive drug group was administered 0.1 mL each of the novel polypeptide solution, physiological saline, and new recovery liquid twice a day. The ulcer surface was observed for healing after 1 day, 3 days, and 5 days. The ulcer was scored as follows: 1 point for no congestion or edema and an ulcer surface diameter of less than 1 mm, 2 points for mild congestion and edema and an ulcer surface diameter of 1-2 mm, 3 points for moderate congestion and edema and an ulcer surface diameter of 2-3 mm, and 4 points for severe congestion and edema and an ulcer surface diameter of 3 mm or more. The results are shown in Table 4. JPEG2024543723000006.jpg66164Note: Compared to the model group, *P<0.05 indicates significant difference. The test results showed that the novel polypeptide TRF7 could significantly promote the healing of oral ulcers in rats, with a significant difference from the model group and superior to the new recovery liquid.
[0026] Example 9 Acute toxicity test of novel polypeptides TRF1 to TRF12 Test method: Kunming mice weighing 18-22g (purchased from the Guangdong Medical Experimental Animal Center) were taken and randomly divided into groups of 10 mice. Different doses of TRF1-TRF12 were orally administered to the mice, and the median lethal dose (LD) was calculated based on the survival rate of the mice. 50 The median lethal dose was calculated by the following formula: median lethal dose (mg / kg) = (the dose at which half of the mice died / the body weight of the mouse). Test results: The novel polypeptides TRF1 to TRF12 showed no deaths or serious side effects in mice at a dose of 500 mg / kg, and showed LD 50 was shown to have low toxicity at levels exceeding 500 mg / kg (Table 5). JPEG2024543723000007.jpg34161
[0027] Example 10: Skin safety evaluation of novel polypeptide TRF7 Subjects: 20 subjects, aged 18-55 years, 10 women and 10 men. The subjects had healthy skin, had no history of skin allergies, and met the criteria for voluntary subject enrollment. Test method: A qualified patch device was selected, and the closed patch test method was used, in which approximately 0.020-0.025 mL (2 mg / mL) of the polypeptide TRF7 was dripped onto the patch device, and a special topical tape was applied to the subject's back. After 24 hours, the test product was removed, and the skin reaction was observed 0.5, 6, 12, 24, and 48 hours after removal, and the results were recorded according to the skin reaction grading criteria of the "Cosmetic Hygiene Standards". Test results: Patch tests were performed on 20 subjects, and the skin reactions were observed after 0.5, 6, 12, 24, and 48 hours. No side effects were observed on the skin, demonstrating that the novel polypeptide TRF7 of the present invention is safe for the skin.
[0028] Example 11 Preparation of tablets 0.1 g of polypeptide TRF7, 40 g of lactose, 60 g of starch slurry, and 0.2 g of magnesium stearate were taken, mixed, sieved, dried, and made into tablets, each tablet containing 0.001 g of TRF7.
[0029] Example 12 Preparation of injections 0.1 g of polypeptide TRF7 and 50 g of propylene glycol were pulverized, diluted with 100 mL of water for injection, mixed well, and then 9 g of sodium chloride was added to dissolve. Water for injection was then added to make the total volume 1000 mL, the pH was adjusted to 5.5 to 6.5, filtered, potted, and sterilized to obtain 1000 vials of injection preparation.
[0030] Example 13 Preparation of solid lipid nanoparticles 0.1 g of polypeptide TRF7 was taken, 500 mg of soybean lecithin was added, and dissolved in 25 mL of ethanol. 200 mg of stearic acid and 500 mg of soybean lecithin were dissolved in 25 mL of cyclohexane, and mixed and stirred well. In a constant temperature water bath at 37 ° C, the organic solvent was removed by rotary evaporation under reduced pressure, so that the drug and additives formed a uniform lipid film on the wall of the flask, and the flask was placed in a vacuum desiccator overnight to completely remove the organic solvent. Further, 3750 mg of polyethylene glycol monostearate was dissolved in 175 mL of water with stirring, added to the above film, and sonicated for 10 minutes, and the volume was adjusted to 250 mL to obtain a pale yellow transparent solution. This solution was freeze-dried to obtain a freeze-dried powder. The solution was ground in a ball mill for 24 hours to obtain nanoparticles of uniform particle size, which were then mixed and packaged in small portions. Each bag contains 0.001 g of TRF7.
[0031] Example 14 Preparation of controlled release capsules 0.1 g of polypeptide TRF7 was successively added with 40 g of lactose and 10 g of starch slurry, and directly loaded into a rotary granulator coating machine to prepare pellets, and a suspension of a coating agent of plasticized ethyl cellulose diluted to 15% solids by weight was sprayed onto the rotating bed of polypeptide pellets. During spraying, the pellets were film-coated with a dispersion carrier made of poloxamer 188, forming sustained-release pellets with an average particle size of about 450 μm. The mixture was thoroughly mixed and filled into capsules, each of which contained 0.001 g of TRF7.
[0032] Example 15 Preparation of a Topical Gel Cream 2 g of glycerin was weighed out, 0.75 g of polyacrylic acid and 0.1 g of aluminum hydroxide were added in that order, and mixed thoroughly. Then, 0.2 g of polypeptide TRF7 was added and mixed thoroughly under vacuum conditions to obtain [1]. 5 g of purified water was further weighed out, and 0.06 g of lactic acid and 0.1 g of sodium carboxymethylcellulose were dissolved in water to obtain [2]. [2] was added to [1] and mixed thoroughly under vacuum conditions to obtain a drug-containing cream by crosslinking reaction. The drug-containing cream was coated (so that the thickness of the drug-containing cream was about 1.0 mm), cut to the specifications of a conventional gel, and the amount of drug contained in each gel was 0.02 g, dried, and packaged.
[0033] Example 16 Preparation of an ointment 40 g of stearyl alcohol and 45 g of white petrolatum were dissolved in a water bath and heated to 75° C. 1.46 g of sodium dodecyl sulfate, 0.025 g of hydroxybenzyl ester, 0.015 g of hydroxybenzyl propyl ester, 13 g of propylene glycol, and 0.2 g of polypeptide TRF7 were successively dissolved in water and heated to 75° C., after which stearyl alcohol and white petrolatum at 75° C. were added and stirred until cooled to give an ointment containing 0.2% TRF7.
[0034] Example 17 Preparation of liniment 0.1 g of the polypeptide TRF7 was dissolved in 45 mL of distilled water and filtered. 5 mL of glycerol and 1 mL of nitrogen ketone were added to the filtrate, and the mixture was supplemented with distilled water until the volume reached 50 mL to prepare a liniment containing 0.2% TRF7.
[0035] Example 18 Preparation of Bandage Stearic acid polyhydroxy 40 ester 2g, polysorbate 80 2g, poloxamer 188 1g, sodium dihydrogen phosphate 0.3g, ethylhydroxybenzene 0.1g, and purified water 50mL were weighed, sterilized by heating at 130℃ for 30-60 minutes, cooled to 30-40℃, and stirred uniformly to obtain [1]. Light liquid paraffin 10g, stearyl alcohol 0.5g, stearyl alcohol 0.5g, white petrolatum 3g, and glyceryl monostearate 1g were weighed, sterilized, and kept at 30-40℃ to obtain [2]. Polypeptide TRF7 0.1g was dissolved in distilled water 50mL, filtered, added to [1], and stirred to obtain [3]. [2] was slowly added to [3], 3 g of 15% ethanol was added, and the mixture was rapidly stirred to adjust the pH to 6.0. The temperature was kept at 45°C, high-speed shearing was performed, emulsification was performed for 5 minutes, and the mixture was stirred and cooled to 30-35°C to prepare a white, uniform cream liquid. The cream liquid was poured into a charging plate, and the inner pad was coated with the cream liquid using a coating machine, dried at low temperature (45°C), and cut to the required size to obtain an inner pad coated with the drug. The coated inner pad was attached to the center of the base fabric, and release paper was attached to the adhesive parts at both ends of the base fabric.
[0036] Example 19 Preparation of Facial Cream 0.1g of polypeptide TRF7 was prepared, mixed with 1g of No.26 white oil, 1g of stearyl alcohol, 1g of stearic acid, 0.5g of monoglycerin, 0.05g of 350 silicone oil, 0.5g of GTCC, and 0.03g of methylnipazine, and heated to 90°C to prepare a first semi-finished product. 4g of deionized water, 0.1g of polypeptide TRF7, 0.3g of pimelic acid O-20, and 0.5g of glycerol were added to the first semi-finished product, and heated to 80°C to prepare a second semi-finished product. The second semi-finished product was homogenized twice at 80°C (rotation speed 3000 rpm, time 10 minutes), and then stirred for 30 minutes, cooled to 45°C, and creamed, and then 0.005g of Kazon was added and mixed uniformly to prepare 1% polypeptide-containing creams.
[0037] Example 20 Preparation of a facial mask 0.1 g of the polypeptide TRF7 was dissolved in 10 mL of deionized water and filtered. The filtrate was mixed with 0.3 g of carbomer moistened with glycerin, the pH was adjusted to 6-7 by adding triethanolamine, and the mixture was evenly applied onto mask paper to prepare masks containing 0.01 g of the polypeptide per sheet.
[0038] Example 21 Preparation of lotion 0.1g of polypeptide TRF7 was taken and made into a 0.2mg / mL aqueous solution. 5g of glycerol was added to 1g of hyaluronic acid to disperse it, and water was added to dissolve it, and the mixture was stirred well to obtain a hyaluronic acid solution. 1g of trehalose and 1g of allantoin were dissolved in water, mixed with the above hyaluronic acid solution, and stirred well to obtain a mixed solution. Polypeptide solution, 1g of D-panthenol, 10g of oat β-glucan, 10g of 1,2 pentanediol, and 0.05g of preservative were added in order to the above mixed solution, and water was added and the mixture was stirred well to obtain the above mixed solution.
[0039] Example 22 Preparation of Lotion (1) 0.1 g of the polypeptide TRF7 was dissolved in 0.2 mg / mL of water. (2) 0.05 g of sodium hyaluronate was dissolved and dispersed in water and thoroughly stirred to obtain a hyaluronic acid solution. (3) 5 g of glycerol, 3 g of butanediol, 2 g of trehalose, 0.2 g of allantoin, and 0.1 g of thickener were dissolved in water and heated to 75°C. (4) 2 g of jojoba seed oil, 3 g of hydrogenated polydecene, 2 g of polydimethylsiloxane, 3 g of caprylic / capric acid triglyceride, and 3 g of emulsifier were heated to 75° C. and stirred uniformly. (5) The mixture prepared in step (3) was quickly poured into the mixture prepared in step (4), homogenized at a constant temperature for 3 to 5 minutes, and then cooled. (6) Cool to below 60°C, add (1) and (2), homogenize, cool to below 40°C, and add preservatives and fragrance to obtain a lotion.
[0040] Example 23 Preparation of cleansing gel 0.1 g of polypeptide TRF7 was made into a 0.2 mg / mL aqueous solution, and the above polypeptide aqueous solution, 2.5 g of glycerol, 3 g of decyl glucoside, 3 g of sodium cocoyl malic acid amino acid, 1.5 g of sodium laureth sulfate, 0.1 g of solubilizer, and 0.05 g of fragrance were added sequentially to water and stirred, after which 0.5 g of thickener was added and stirred until completely dissolved, to obtain a cleansing gel.
[0041] Example 24 Evaluation of the cosmetic effects of a novel polypeptide lotion 1.1 Test product: Polypeptide lotion prepared in Example 22 of the present invention 1.2 Subjects: 30 subjects, 18 women and 12 men, aged between 18 and 55 years. The subjects had unsightly skin conditions such as wrinkles, pigmentation, dullness, and scars from minimally invasive or post-surgical procedures. 1.3 Test method: After cleansing the skin of the subject, apply the lotion prepared in Example 22 to the skin and observe and feel the effect of use. 1.4 The results of the test evaluation are shown in Table 6. JPEG2024543723000008.jpg55164The subjects reported that the use of the novel polypeptide TRF7 lotion product increased skin moisture content, improved skin hydration and elasticity, and improved skin hydration and moisturization. The product also had whitening effects and wrinkle, scar, and pigmentation removal effects. No allergies were reported in the subjects.
[0042] Example 25 Evaluation of the cosmetic effects of a novel polypeptide mask 1.1 Test product: Facial mask prepared in Example 20 of the present invention. 1.2 Subjects: 30 subjects, 21 women and 9 men, aged between 18 and 58 years old. The subjects' facial skin had unsightly skin conditions such as wrinkles, pigmentation, dullness, and scars from minimally invasive surgery and surgery. 1.3 Test method: After washing the face of the subject, the novel polypeptide mask prepared in Example 20 was applied to the face once a day, and the effect of use was observed and felt. 1.4 The results of the test evaluation are shown in Table 7. JPEG2024543723000009.jpg55164 Subjects reported that using the novel polypeptide TRF7 mask product increased skin moisture content, improved skin hydration and elasticity, and improved skin hydration and moisturization. The product also demonstrated whitening effects and wrinkle, scar, and pigmentation removal. No allergies were reported in subjects.
[0043] The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples. Other changes, modifications, substitutions, combinations and simplifications made without departing from the spirit and principles of the present invention are equivalent substitutions, and all are intended to be included in the protection scope of the present invention.
Claims
1. A novel polypeptide for promoting tissue repair, comprising: The novel polypeptide is characterized in that it has the following structure: Where: R 1 = H, Ala, Gly, Ala - Ala - or Val - Ala -, R 2 = Asn or Asp, R3=Ser, Tyr, -Gly-Ser-Tyr, -Gly-Ser-Tyr-Ala-Pro-Leu-Gly-Tyr, -Gly-Ser-Tyr-Ala-Pro-Leu-Gly-Tyr-Hi s-Val-Arg, or -Gly-Ser-Tyr-Ala-Pro-Leu-Gly-Tyr-His-Val-Arg-Glu-Tyr-Pro-Ala-Gly-Val-Ser-Ala-Ala.
2. 2. The novel polypeptide according to claim 1, characterized in that the novel polypeptide has a structure shown in any one of TRF1 to TRF12.
3. 3. Use of the novel polypeptide according to claim 1 or 2 in the preparation of a product for promoting tissue repair or improving the aesthetic appearance of the skin.
4. 4. Use of the novel polypeptide according to claim 3 in the preparation of a product for promoting tissue repair or improving skin aesthetics, wherein the product is a pharmaceutical product, a medical device or a daily chemical product.
5. Use of the novel polypeptide described in claim 4 in the preparation of a product for promoting tissue repair or improving skin aesthetics, wherein the pharmaceutical, medical device or daily chemical product contains an effective amount of one or more of the novel polypeptides, or a pharma- ceutically acceptable salt or stereoisomer thereof, with the remainder being additives or other compoundable drugs.
6. Use of the novel polypeptide described in claim 4 in the preparation of a product for promoting tissue repair or improving skin aesthetics, wherein the pharmaceutical, medical device or daily chemical product is a tablet, capsule, injection, liposome nanoparticle, controlled release agent, gel cream, ointment, liniment, patch, cream, cleanser, lotion, gel or lotion.
7. 6. Use of the novel polypeptide according to claim 5 in the preparation of a product for promoting tissue repair or improving skin aesthetics, wherein the additive is a solvent, a disintegrant, a flavor corrector, a preservative, a colorant or a binder.
8. A pharmaceutical composition comprising the novel polypeptide according to claim 1 or 2 and a pharma- ceutically acceptable carrier.
Citation Information
Patent Citations
New Periplaneta Americana polypeptide capable of promoting tissue repair, and applications thereof
CN106977586A
Novel polypeptide PAP1 and application thereof
CN107266532A
Small molecular polypeptide promoting skin damage repair and application thereof
CN107973838A
Application of histatin 1 (Hst1) polypeptide in preparation of composite materials for promoting repair of large-area skin defects
CN108785657A
Insect CPCFC family epidermal protein, coding nucleotide sequence and application of insect CPCFC family epidermal protein
CN113321718A
